Company Website:
http://www.zlk.com
NEW YORK -- (Business Wire)
Levi & Korsinsky, LLP announces it has commenced an investigation of
XBiotech Inc. (“XBiotech”) (NASDAQ:XBIT) concerning possible violations
of federal securities laws.
On April 20, 2017, XBiotech announced that the European Medicines Agency
rendered a negative trend vote after meeting with the Company to discuss
its marketing authorization application ("MAA") for XBiotech's candidate
antibody for the treatment of colorectal cancer. The negative trend vote
indicates that it is unlikely that the Committee for Medicinal Products
for Human Use will vote in favor of the MAA at its formal decision vote
scheduled for May. Following this news, shares of XBiotech were down
more than 40% on intraday trading on April 21, 2017. To obtain
additional information, go to:
http://zlk.9nl.com/xbiotech
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York,
Connecticut, California and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170421005774/en/
Contacts:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq., 212-363-7500
Toll
Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com
Source: Levi & Korsinsky, LLP
© 2024 Canjex Publishing Ltd. All rights reserved.